References

1. Cambau E, Saunderrson P, Matsuoka M, Cole ST, Kai M, et al (2018). Antimicrobial

resistance in leprosy: results of the first prospective open survey conducted by a WHO
surveillance network for the period 2009-2015. Clin Microbiol Infect.24(12):1305-10.
2. Eichelmann K, González SE, Salas-Alanis, JC (2013). Leprosy. An update: definition,
pathogenesis, classification, diagnosis, and treatment. Actas Dermosifiliogr.104(7):554-63.
3. Eichelmann K, González SE, Salas-Alanis, JC (2013). Leprosy. An update: definition,
pathogenesis, classification, diagnosis, and treatment. Actas Dermosifiliogr.104(7):554-63.
4. Girao RJS, Soares NLR, Pinheiro JV, Oliveira GDP, Carvalho SMF, et al (2013). Leprosy
treatment dropout: a systematic review. International Archieves of Medicine.6:1-9.
5. Heukelbach J, Chichava OA, Oliveira ARD, Hafner K, Walther F, et al (2011). Interruption
and defaulting of multidrug therapy against leprosy: population-based study in brazil
savannah region. PLoS Neglected Tropical Disease.5(5): 1-9.
6. Kementrian kesehatan RI (2012). Pedoman nasional program pengendalian penyakit kusta.
Kemenkes, p111-21.
7. Lee DJ, Rea TH, Modlin RL (2012). Leprosy. In:. Fitzpatrick’s dermatology in general
medicine, 8th ed (Goldsmith LA, Katz SI, eds). McGraw Hill, New York, pp2253-62.
8. Lockwood DN (2010). Leprosy. In: Rook’s textbook of dermatology, 8th ed (Burns T,
Breathnach S, Cox N, Griffiths C, eds). Wiley-Blackwell, Oxford, pp32.1-19.
9. Massone C, Belachew WA, Schettini A (2015). Histopathology of the lepromatous skin
biopsy. Clinics in Dermatology. 33:38-45.
10. Matsuoka M (2010). Drug resistance in leprosy. Jpn K Infect Dis.63:1-7.
11. Naaz F, Mohanty PS, Bansal AK, Kumar D, Gupta UD (2017). Challenges beyond
elimination in leprosy. Int J Mycobacteriol.6:222-8.
12. Pusat Data dan Informasi Kementrian Kesehatan RI (2018). Hapuskan stigma dan
diskriminasi terhadap kusta. Kemenkes, p1-11.
13. Siskawati Y, Effendi EH, Legiawati L, Menaldi SL (2018). Poor treatment compliance
leads to higher mutation for rifampicin resistance in multibacillary leprosy paients. Med J
Indones.27(4):237-43.
14. William DL, Gillis TP (2012). Drug Resistance leprosy: monitoring and current status.
Lepr Rev.83:269-81.
15. World Health Organization (2012). WHO expert committee of leprosy: Eight report. WHO,
Geneva, p45.